Preview Mode Links will not work in preview mode


Sep 30, 2014

Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014

Sep 28, 2014

For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014

Sep 25, 2014

For patients with wild type EGFR, meaning there is no EGFR mutation, drugs like Tarceva (erlotinib) can have a small benefit, but Dr. Joan Schiller wants research to do better. February 2014

Sep 23, 2014

Eighty percent of lung cancer patients have wild type EGFR, meaning there is no EGFR mutation. Dr. Joan Schiller of UT Southwestern Medical Center discusses a new drug in development that may help those patients. February 2014

Sep 21, 2014

The stigma of lung cancer can lead to shame, fear, and sub-optimal care. Dr. Joan Schiller wants us all to get past it, and she's leading the charge to make that happen. February 2014.